Subscribe To

Price Alert Latest News Economic Calendar News

ORGS / Orgenesis (ORGS) Q3 2022 Earnings Call Transcript

Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Orgenesis Third Quarter 2022 Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Mr. Read More

Demo Live Account See Partner Details

Content Topics

Orgenesis

ORGS

2022

Earnings

Call

Transcript

orgs

Stock

Posted: Nov 13 2022, 21:29

Author Name: Seeking Alpha

ORGS News

By 24/7 Wall Street
November 23, 2022

New Dimensions Trading Discloses Large Position in ORGS / Orgenesis

Fintel reports that New Dimensions Trading has filed a 13G form with the SEC disclosing ownership of 1,370,000 shares of Orgenesis Inc (ORGS).

By Seeking Alpha
November 13, 2022

Orgenesis (ORGS) Q3 2022 Earnings Call Transcript

Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman - Investor Relations Vered C

By Proactive Investors
May 24, 2022

Orgenesis enters second phase of POCare Platform rollout; sees recurring revenues from long-term contracts for the next 2-3 years

Orgenesis (NASDAQ:ORGS) Inc, the global biotech company working to unlock the full potential of cell and gene therapies, has said it is entering the s

By Proactive Investors
May 3, 2022

Orgenesis says consortium led by its MIDA Biotech subsidiary wins 4 million euro grant supporting cutting edge technology

Orgenesis (NASDAQ:ORGS) Inc said that a consortium led by its subsidiary, MIDA Biotech, has won a 4-million-euro grant under the European Innovation

By Proactive Investors
March 31, 2022

Orgenesis inks agreement with certain investors for a private placement for which it expects to receive gross proceeds of approximately $14.8M

Orgenesis (NASDAQ:ORGS) Inc said it has entered into a definitive securities purchase agreement with certain investors for a private placement for whi

By Seeking Alpha
March 30, 2022

Orgenesis' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript

By Proactive Investors
March 30, 2022

Orgenesis sees revenue and profits soar in 2021 as its Point of Care platform gains traction around the globe

Orgenesis (NASDAQ:ORGS) Inc reported a more than four-fold increase in revenue in 2021 from a year earlier, thanks to growing uptake of its Point o

By Proactive Investors
January 27, 2022

Orgenesis achieves latest milestone in its collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

Orgenesis (NASDAQ:ORGS) Inc said it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitari

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.